NasdaqGM:CHRS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide.


Snowflake Analysis

Undervalued with high growth potential.


Similar Companies

Share Price & News

How has Coherus BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CHRS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.3%

CHRS

0.4%

US Biotechs

2.3%

US Market


1 Year Return

-4.9%

CHRS

28.5%

US Biotechs

6.7%

US Market

Return vs Industry: CHRS underperformed the US Biotechs industry which returned 28.5% over the past year.

Return vs Market: CHRS underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

CHRSIndustryMarket
7 Day-0.3%0.4%2.3%
30 Day11.5%10.3%6.0%
90 Day21.0%23.2%18.9%
1 Year-4.9%-4.9%29.8%28.5%9.0%6.7%
3 Year35.3%35.3%31.8%27.5%36.6%27.7%
5 Year-51.8%-51.8%-5.1%-10.5%64.2%46.1%

Price Volatility Vs. Market

How volatile is Coherus BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Coherus BioSciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CHRS ($17.93) is trading below our estimate of fair value ($59.51)

Significantly Below Fair Value: CHRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CHRS is good value based on its PE Ratio (8.6x) compared to the US Biotechs industry average (19.4x).

PE vs Market: CHRS is good value based on its PE Ratio (8.6x) compared to the US market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: CHRS is good value based on its PEG Ratio (0.4x)


Price to Book Ratio

PB vs Industry: CHRS is overvalued based on its PB Ratio (8.1x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Coherus BioSciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

23.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CHRS's forecast earnings growth (23.4% per year) is above the savings rate (2.2%).

Earnings vs Market: CHRS's earnings (23.4% per year) are forecast to grow faster than the US market (22.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CHRS's revenue (11.9% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: CHRS's revenue (11.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CHRS's Return on Equity is forecast to be high in 3 years time (27.5%)


Next Steps

Past Performance

How has Coherus BioSciences performed over the past 5 years?

20.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CHRS has a high level of non-cash earnings.

Growing Profit Margin: CHRS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CHRS has become profitable over the past 5 years, growing earnings by 20.3% per year.

Accelerating Growth: CHRS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CHRS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: Whilst CHRS's Return on Equity (92.46%) is outstanding, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is Coherus BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: CHRS's short term assets ($395.2M) exceed its short term liabilities ($119.0M).

Long Term Liabilities: CHRS's short term assets ($395.2M) exceed its long term liabilities ($190.3M).


Debt to Equity History and Analysis

Debt Level: CHRS's debt to equity ratio (113.8%) is considered high.

Reducing Debt: Insufficient data to determine if CHRS's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: CHRS's debt is well covered by operating cash flow (55.2%).

Interest Coverage: CHRS's interest payments on its debt are well covered by EBIT (10.2x coverage).


Balance Sheet


Next Steps

Dividend

What is Coherus BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CHRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CHRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CHRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CHRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CHRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Denny Lanfear (65yo)

9.83yrs

Tenure

US$5,361,707

Compensation

Mr. Dennis M. Lanfear, also known as Denny, has been the Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Cap ...


CEO Compensation Analysis

Compensation vs Market: Denny's total compensation ($USD5.36M) is about average for companies of similar size in the US market ($USD4.72M).

Compensation vs Earnings: Denny's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Dennis Lanfear
Chairman9.83yrsUS$5.36m0.90% $11.5m
Jean-Frédéric Viret
Chief Financial Officer5.83yrsUS$1.83m0.022% $274.6k
Vincent Anicetti
Chief Operating Officer2.17yrsUS$1.81m0.024% $310.2k
Vladimir Vexler
Chief Scientific Officer1.67yrsUS$1.76m0.035% $447.0k
V. Lawlis
Science Director7.67yrsUS$243.90kno data
Peter Watler
Chief Technical Officer6.08yrsUS$971.52kno data
David Arrington
Vice President of Investor Relations & Corporate Affairsno datano datano data
Thomas Fitzpatrick
Chief Legal Officer1.33yrsno datano data
Erik Wiberg
Executive Vice President of Corporate Development3.33yrsno datano data
Chris Thompson
Senior Vice President of Salesno datano datano data
Barbara Finck
Chief Clinical Advisorno dataUS$1.55mno data
Michael Chen
Senior Vice President of Commercial Analytics & Tradeno datano datano data

3.3yrs

Average Tenure

65yo

Average Age

Experienced Management: CHRS's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dennis Lanfear
Chairman9.83yrsUS$5.36m0.90% $11.5m
V. Lawlis
Science Director7.67yrsUS$243.90kno data
Barbara Finck
Chief Clinical Advisorno dataUS$1.55mno data
James Healy
Independent Director6.42yrsUS$216.40k0.099% $1.3m
Mats Wahlström
Lead Independent Directorno dataUS$261.40kno data
William Bennett
Member of Scientific Advisory Boardno datano datano data
Mary Szela
Independent Director6yrsUS$226.40kno data
Ali Satvat
Independent Director6.17yrsUS$216.40kno data
James Daly
Executive Chairman of Commercial Advisory Committee4.42yrsno datano data
Alan Herman
Chairman Emeritus & Member of Advisory Board1.67yrsUS$1.19mno data
Christos Richards
Director9.33yrsUS$206.40k0.090% $1.1m
Andrew J. Jones
Member of Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

65yo

Average Age

Experienced Board: CHRS's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CHRS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Coherus BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Coherus BioSciences, Inc.
  • Ticker: CHRS
  • Exchange: NasdaqGM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.271b
  • Shares outstanding: 70.91m
  • Website: https://www.coherus.com

Number of Employees


Location

  • Coherus BioSciences, Inc.
  • 333 Twin Dolphin Drive
  • Suite 600
  • Redwood City
  • California
  • 94065
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CHRSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 2014
8C5DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body’s ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/13 07:11
End of Day Share Price2020/07/10 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.